TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, Garavaglia C, Squadrito ML, Fedeli M, Consonni M, Sesana S, Re F, Shen H, Dellabona P, Casorati G.
Delfanti G, et al. Among authors: de lalla c.
Sci Immunol. 2022 Aug 12;7(74):eabn6563. doi: 10.1126/sciimmunol.abn6563. Epub 2022 Aug 19.
Sci Immunol. 2022.
PMID: 35984893